Biogen stock edges lower despite RayThera partnership

Traders Union
All News
Business & Wealth
Companies
Biogen stock edges lower to $206.28

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

07.08.2026

Biogen stock edges lower despite RayThera partnership — Biogen stock edges lower to $206.28

Biogen announced the completion of its acquisition of RayThera Inc on July 13, 2026. Meanwhile, the stock edges lower on the day, trading at $206.28.

BIIB price prediction

24H 0.38%

$254.59

48H 0.51%

$254.91

7D 0.16%

$254.02

1M 6.79%

$270.83

3M 25.39%

$318.01

6M 29.59%

$328.67

12M 57.11%

$398.47

Current price: $253.62 3.86 1.55%

Closed 10/30

Daily range 251.19

258.73

Weekly range 243.55

258.73

Loading...

Highlights

Biogen completed its acquisition of RayThera Inc, adding new immune-mediated disease assets to its immunology portfolio.
Shares of Biogen edged lower, ending at $206.28 despite the strategic transaction announcement.
The stock remains in a bullish technical structure but faces overbought signals, with next week's range expected between $200.64 to $211.91.

Biogen announced the completion of its acquisition of RayThera Inc. The announcement was made directly by the company. The transaction adds multiple potential assets for immune-mediated diseases to its immunology portfolio.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Upside capped as overbought conditions check bullish momentum

Biogen stock remains above its MA-20 at $202.88, with the daily setup holding bullish as prices also stay above the MA-50 and MA-200. Despite this positive structure, the CCI at 103.2 signals overbought conditions, which limits the potential for further upside. The daily price move runs against this broader bullish backdrop, reinforcing that upside is currently constrained.

Upside bias remains as weekly outlook strengthens above key support

Traders should monitor whether Biogen stock can sustain its wide intraday range between $202.26 and $209.48 as the next test of direction. A close above $212.18 would indicate buyers are committed, while a drop below $202.88 would suggest the move is being faded. Even though the recent action was a contained move within a narrow range, the outlook for the coming trading week points to an upside probability of more than 80% and a downside probability of less than 20%, with an expected range of $200.64 to $211.91. On the weekly chart, the longer-term picture stays firmly constructive.

Previously it was reported that Biogen was exhibiting a broadly bullish technical structure, with traders watching for potential directional moves. The completion of the RayThera acquisition adds to the longer-term positive setup, and traders should now monitor whether the stock can maintain its constructive weekly trend despite near-term overbought signals.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Biogen

Editor's Picks for You

Can Bitcoin make you a millionaire?

By Pavlo Kot
9 hours ago

Can Bitcoin make you a millionaire?

Editors' Picks

France's crypto market matures as regulation reshapes the industry

By Olena Litvinenko
Yesterday

France's crypto market matures as regulation reshapes the industry

Editors' Picks

SK Hynix’s rise reshapes the global chip industry and economy

By Dmytro Kharkov
Yesterday

SK Hynix’s rise reshapes the global chip industry and economy

Editors' Picks

All Editors' Top Picks

Latest Biogen News

Biogen announces live webcast for Q3 2026 financial results: Can BIIB break above $254.45?

By Yaroslav Dmytrenko
28.10.2026

Biogen announces live webcast for Q3 2026 financial results: Can BIIB break above $254.45?

Companies

Biogen New Ventures takes part in Series A funding for Estuary Biotherapeutics: Can BIIB break above $240.99?

By Mykhailo Ihnatenko
16.10.2026

Biogen New Ventures takes part in Series A funding for Estuary Biotherapeutics: Can BIIB break above $240.99?

Companies

Biogen stock trades up toward $207.56 with buyers in control above MA-20 and Kijun support

By Ezequiel Gomes
05.08.2026

Biogen stock trades up toward $207.56 with buyers in control above MA-20 and Kijun support

Companies

All Biogen News

Pavlo Kot
9 hours ago

Can Bitcoin make you a millionaire?

Olena Litvinenko
Yesterday

France's crypto market matures as regulation reshapes the industry

Dmytro Kharkov
Yesterday

SK Hynix’s rise reshapes the global chip industry and economy

Eugene Komchuk
Yesterday

Binance hack: The biggest theft in crypto history

Ksenia Gerey
29.10.2026

From PlayStation to crypto: Why Sony is building its own blockchain

Daria Chernytska
4 min ago

S&P 500 closes down 1.8 percent wiping out about $1.2 trillion, Peter Tuchman notes

Mykhailo Ihnatenko
29 min ago

Layah Heilpern: Binance replenishes 90% of stolen assets

Igor Krasulya
29 min ago

Lourdes Sánchez: Binance draws attention after $6.3 billion is questioned, A7 International continues business

Ksenia Gerey
33 min ago

Buy the dip remains the approach, James E. Thorne advises

Hanna Syniavska
44 min ago

Laura Shin: AI agents could make censorship-resistant money more valuable over time

Top News

Ivan Andriyenko
1 hour ago

Apple overtakes Nvidia as world's most valuable company with market cap above $5 trillion

Apple overtakes Nvidia as world's most valuable company with market cap above $5 trillion

Daria Chernytska
1 hour ago

Intel shares plunge 29% after earnings report in worst drop since 1974

Intel shares plunge 29% after earnings report in worst drop since 1974

Anastasiia Chabaniuk
7 hours ago

Fitch cuts France's rating outlook to negative over deficit and debt risks

Fitch cuts France's rating outlook to negative over deficit and debt risks

Kyle Torpey
7 hours ago

Trump says U.S. probes possible North Korean role in $6.3 billion Binance hack

Trump says U.S. probes possible North Korean role in $6.3 billion Binance hack

Pavlo Kot
9 hours ago

Can Bitcoin make you a millionaire?

Can Bitcoin make you a millionaire?

Top 5 companies for you

United States

Live News

Andrey Mastykin
Now

Eurozone economy slows as France slips into recession fears

Anton Kharitonov
Now

EUR/USD recovery stalls near 1.1210 as dollar retains its fundamental advantage

Anastasiia Chabaniuk
Now

Binance launches stolen asset recovery and allocates $6.34 billion to cover losses

Mykhailo Ihnatenko
Now

AMD stock drops over 7% as Intel outlook hits semiconductor sentiment

Jose Antonio Gastelum
Now

Circle phases out old USDC bridge as CCTP V2 takes over

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.